This antibody directed to platelet derived growth factor-DD (PDGF-DD) can be potentially used in diagnosis and treatment of renal fibrosis, renal dysfunction or renal injury.
Figure 1 PDGF-D stimulates the proliferation of rat fibroblasts in vitro .
Incorporation of BrdU in growth-arrested rat fibroblasts NRK-49F after stimulation with PDGF-BB and -DD (10 and100 ng/ml, respectively) with or without the anti-PDGF-D fully human monoclonal antibody CR002 (1 μg/ml).
Boor, P., Konieczny, A., Villa, L., Kunter, U., van Roeyen, C. R., LaRochelle, W. J., ... & Floege, J. (2007). PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrology Dialysis Transplantation, 22(5), 1323-1331.
Figure 2 Development of proteinuria was transiently decreased by CR002.
Proteinuria was significantly ameliorated by the treatment at days 49, 56 and 77. Arrows indicate the time points of CR002 administration. The insert shows the concentration of circulating CR002 on days 42, 49 and 56 and the grey area represents the approximate duration of effective PDGF-D inhibition.
Boor, P., Konieczny, A., Villa, L., Kunter, U., van Roeyen, C. R., LaRochelle, W. J., ... & Floege, J. (2007). PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrology Dialysis Transplantation, 22(5), 1323-1331.
Figure 3 Sirius red staining ( A , B ) and specific immunohistochemistry for collagen type I ( C , D) and III ( E , F ), vimentin ( G , H ) and α-SMA ( I , J ) in IgG-treated control animals (images A, C, E, G, I) or CR002-treated animals (B, D, F, H, J).
Boor, P., Konieczny, A., Villa, L., Kunter, U., van Roeyen, C. R., LaRochelle, W. J., ... & Floege, J. (2007). PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrology Dialysis Transplantation, 22(5), 1323-1331.
Figure 4 Renal interstitial fibrosis as detected by Sirius red staining.
Morphometric evaluation of Sirius red–positive area in the renal cortex.
Ostendorf, T., Rong, S., Boor, P., Wiedemann, S., Kunter, U., Haubold, U., ... & Alvarez, E. (2006). Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. Journal of the American Society of Nephrology, 17(4), 1054-1062.
Figure 5 Expression of desmin at the glomerular edge on day 56 after disease induction.
Ostendorf, T., Rong, S., Boor, P., Wiedemann, S., Kunter, U., Haubold, U., ... & Alvarez, E. (2006). Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. Journal of the American Society of Nephrology, 17(4), 1054-1062.
Figure 6 Renal cortical deposition of type III collagen.
Morphometric evaluation of the area that stained positively for type III collagen in the renal cortex.
Ostendorf, T., Rong, S., Boor, P., Wiedemann, S., Kunter, U., Haubold, U., ... & Alvarez, E. (2006). Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. Journal of the American Society of Nephrology, 17(4), 1054-1062.
Figure 7 Renal cortical deposition of type III collagen.
Morphometric evaluation of the area that stained positively for fibronectin in the renal cortex.
Ostendorf, T., Rong, S., Boor, P., Wiedemann, S., Kunter, U., Haubold, U., ... & Alvarez, E. (2006). Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. Journal of the American Society of Nephrology, 17(4), 1054-1062.
Figure 8 Renal interstitial detection of membrane attack complex (C5b-9).
Morphometric evaluation of C5b-9 –positive area in the renal cortex.
Ostendorf, T., Rong, S., Boor, P., Wiedemann, S., Kunter, U., Haubold, U., ... & Alvarez, E. (2006). Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. Journal of the American Society of Nephrology, 17(4), 1054-1062.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0987CL-S(P) | Anti-Human PDGFD Recombinant Antibody scFv Fragment (CR002) | ELISA | Human antibody |
TAB-0987CL-F(E) | Anti-Human PDGFD Recombinant Antibody Fab Fragment (CR002) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1846CQ | Recombinant Mouse Anti-PDGFD Antibody (11n152) | Neut | IgG1 |
NEUT-1847CQ | Recombinant Mouse Anti-PDGFD Antibody (CBL637) | Neut | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2636 | Hi-Affi™ Recombinant Rabbit Anti-PDGFD Monoclonal Antibody (DS2636AB) | WB, IHC-P | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-1893-FY | Human Anti-PDGFD Recombinant Antibody (HPAB-1893-FY) | Neut | Human IgG |
HPAB-1894-FY | Human Anti-PDGFD Recombinant Antibody (HPAB-1894-FY) | Neut | Human IgG |
HPAB-1895-FY | Human Anti-PDGFD Recombinant Antibody (HPAB-1895-FY) | Neut | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-1893-FY-F(E) | Human Anti-PDGFD Recombinant Antibody; Fab Fragment (HPAB-1893-FY-F(E)) | ELISA, IHC | Human Fab |
HPAB-1894-FY-F(E) | Human Anti-PDGFD Recombinant Antibody; Fab Fragment (HPAB-1894-FY-F(E)) | ELISA, IHC | Human Fab |
HPAB-1895-FY-F(E) | Human Anti-PDGFD Recombinant Antibody; Fab Fragment (HPAB-1895-FY-F(E)) | ELISA, IHC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-1893-FY-S(P) | Human Anti-PDGFD Recombinant Antibody; scFv Fragment (HPAB-1893-FY-S(P)) | ELISA, IHC | Human scFv |
HPAB-1894-FY-S(P) | Human Anti-PDGFD Recombinant Antibody; scFv Fragment (HPAB-1894-FY-S(P)) | ELISA, IHC | Human scFv |
HPAB-1895-FY-S(P) | Human Anti-PDGFD Recombinant Antibody; scFv Fragment (HPAB-1895-FY-S(P)) | ELISA, IHC | Human scFv |
There are currently no Customer reviews or questions for TAB-0987CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.